Amgen Inc. (AMGN) Shares Sold by Sequoia Financial Advisors LLC
Sequoia Financial Advisors LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 18.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,609 shares of the medical research company’s stock after selling 1,036 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Amgen were worth $794,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of AMGN. Bank of New York Mellon Corp grew its stake in shares of Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Amgen by 2.5% in the second quarter. Legal & General Group Plc now owns 3,721,359 shares of the medical research company’s stock valued at $640,938,000 after buying an additional 90,615 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Amgen by 2.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 2,962,595 shares of the medical research company’s stock valued at $510,248,000 after buying an additional 67,815 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Amgen by 3.1% in the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after buying an additional 81,362 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of Amgen by 2.1% in the second quarter. Swiss National Bank now owns 2,690,908 shares of the medical research company’s stock valued at $463,455,000 after buying an additional 54,900 shares in the last quarter. Institutional investors own 78.15% of the company’s stock.
Several research analysts recently commented on AMGN shares. BMO Capital Markets reissued a “market perform” rating and set a $198.00 target price on shares of Amgen in a research note on Thursday, October 26th. Cann reissued a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $203.00 target price on shares of Amgen in a research note on Thursday, September 7th. Mizuho reissued a “buy” rating and set a $198.00 target price (up from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Finally, Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $190.03.
WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/amgen-inc-amgn-shares-sold-by-sequoia-financial-advisors-llc/1714999.html.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at $170.00 on Monday. The company has a market capitalization of $123,404.80, a price-to-earnings ratio of 13.51, a price-to-earnings-growth ratio of 2.46 and a beta of 1.37. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. Amgen Inc. has a fifty-two week low of $138.83 and a fifty-two week high of $191.10.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. Amgen’s quarterly revenue was down .7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.02 EPS. equities research analysts forecast that Amgen Inc. will post 12.66 earnings per share for the current year.
Amgen declared that its Board of Directors has authorized a share repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is presently 41.63%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,050 shares of company stock worth $1,239,673. 0.19% of the stock is owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.